
Denali Therapeutics Inc.
DNLINasdaqCIK 1714899HealthcareFiscal year ends Dec 31
Reports and events: 152 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2024-01-0808:06 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001714899-24-000031 |
| 2023-11-0716:05 ET | 10-Q | Quarterly reportPeriod 2023-09-30 | 0001714899-23-000146 |
| 2023-11-0716:04 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001714899-23-000145 |
| 2023-08-2116:06 ET | 8-K | 1.01 Entry into a material agreement | 0001714899-23-000131 |
| 2023-08-0816:05 ET | 10-Q | Quarterly reportPeriod 2023-06-30 | 0001714899-23-000120 |
| 2023-08-0816:04 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001714899-23-000119 |
| 2023-06-2007:03 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001714899-23-000103 |
| 2023-06-0508:12 ET | 8-K | 8.01 Other events | 0001193125-23-160341 |
| 2023-06-0216:05 ET | 8-K | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001714899-23-000079 |
| 2023-05-0816:06 ET | 10-Q | Quarterly reportPeriod 2023-03-31 | 0001714899-23-000075 |
| 2023-05-0816:03 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001714899-23-000074 |
| 2023-04-1816:02 ET | DEF 14A | Proxy statement | 0001714899-23-000062 |
| 2023-02-2716:06 ET | 10-K | Annual reportPeriod 2022-12-31 | 0001714899-23-000049 |
| 2023-02-2716:04 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001714899-23-000048 |
| 2023-01-0908:08 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001714899-23-000008 |
| 2022-11-0316:07 ET | 10-Q | Quarterly reportPeriod 2022-09-30 | 0001714899-22-000144 |
| 2022-11-0316:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001714899-22-000143 |
| 2022-10-2016:58 ET | 8-K | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-22-026765 |
| 2022-10-1817:09 ET | 8-K | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-22-026572 |
| 2022-08-0816:06 ET | 10-Q | Quarterly reportPeriod 2022-06-30 | 0001714899-22-000123 |
| 2022-08-0816:03 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001714899-22-000122 |
| 2022-07-0508:01 ET | 8-K | 7.01 Regulation FD disclosure | 0001714899-22-000105 |
| 2022-06-0316:01 ET | 8-K | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001714899-22-000082 |
| 2022-05-0516:05 ET | 10-Q | Quarterly reportPeriod 2022-03-31 | 0001714899-22-000078 |
| 2022-05-0516:03 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001714899-22-000077 |
| 2022-04-1916:02 ET | DEF 14A | Proxy statementPeriod 2022-06-02 | 0001714899-22-000068 |
| 2022-03-1616:20 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-22-077264 |
| 2022-02-2817:27 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001628280-22-004300 |
| 2022-02-2816:19 ET | 10-K | Annual reportPeriod 2021-12-31 | 0001714899-22-000058 |
| 2022-02-2816:04 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001714899-22-000056 |
| 2022-02-1406:29 ET | 8-K | 7.01 Regulation FD disclosure | 0001193125-22-039150 |
| 2022-02-1009:01 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001714899-22-000028 |
| 2022-02-0716:03 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001714899-22-000021 |
| 2022-01-1009:06 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001714899-22-000014 |
| 2021-11-1709:03 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001714899-21-000113 |
| 2021-11-0416:07 ET | 10-Q | Quarterly reportPeriod 2021-09-30 | 0001714899-21-000106 |
| 2021-11-0416:04 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001714899-21-000105 |
| 2021-08-0416:07 ET | 10-Q | Quarterly reportPeriod 2021-06-30 | 0001714899-21-000078 |
| 2021-08-0416:03 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001714899-21-000077 |
| 2021-07-2608:29 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001714899-21-000066 |
| 2021-06-0416:04 ET | 8-K | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001714899-21-000058 |
| 2021-05-0508:31 ET | 10-Q | Quarterly reportPeriod 2021-03-31 | 0001714899-21-000054 |
| 2021-05-0308:34 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001714899-21-000050 |
| 2021-04-2208:46 ET | DEF 14A | Proxy statementPeriod 2021-06-02 | 0001714899-21-000042 |
| 2021-02-2608:35 ET | 10-K | Annual reportPeriod 2020-12-31 | 0001714899-21-000033 |
| 2021-02-2516:06 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001714899-21-000022 |
| 2021-02-1207:48 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001714899-21-000018 |
| 2021-02-1015:57 ET | 8-K/A | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001714899-21-000010 |
| 2021-02-0516:43 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-21-030764 |
| 2021-01-1108:46 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001714899-21-000007 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Nov 3, 2026, 19:01 ET. Listed shows no prices and gives no investment advice.